European Medicines Agency committee assesses valproate risks for children of treated fathers.

The EMA's Pharmacovigilance Risk Assessment Committee has completed its review of data concerning potential neurodevelopmental risks. This evaluation focuses on children whose fathers were treated with valproate. The conclusion aims to clarify the drug's safety profile in this specific context.